Diabetes

Molecular therapy for Metabolic diseases: A pharmaceutical mixture encompassing 17-β Estradiol (Estradiol-E2) and/or Pyridoxamine(PM) (E2PM) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 4/February/2017, 9.55 am
Molecular therapy for Metabolic diseases: A pharmaceutical mixture encompassing 17-β Estradiol (Estradiol-E2) and/or Pyridoxamine(PM) (E2PM) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 4/February/2017, 9.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June 8, 2011 Nature [One of…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Triiodothyronine (T3) (PT3) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/February/2018, 9.30 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Triiodothyronine (T3) (PT3) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/February/2018, 9.30 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Sitagliptin (PAS) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 2/February/2018, 11.58 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Sitagliptin (PAS) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 2/February/2018, 11.58 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM:  Triiodothronine (T3), a thyroid hormone, decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 2/February/2018, 12.10 am
Molecular therapy for body weight control, energy homeostasis and TIIDM:  Triiodothronine (T3), a thyroid hormone, decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 2/February/2018, 12.10 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Pantoprazole (brand name: Protonix), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 29/January/2018, 11.18 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: Pantoprazole (brand name: Protonix), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 29/January/2018, 11.18 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Omeprazole(brand name: Prelosec, Losec), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 28/January/2018, 11.08 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: Omeprazole(brand name: Prelosec, Losec), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 28/January/2018, 11.08 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more
Start Typing